Innovation. Expertise. Delivered

T +44 1279 645645
E argenta@crl.com

  • Integrated Drug Discovery

    Integrated Drug Discovery

    A truly integrated approach to small molecule drug discovery from hit identification to pre-clinical candidate.

    Find out more >

  • Medicinal and Synthetic Chemistry

    Medicinal and Synthetic Chemistry

    A wealth of experience in all aspects of drug discovery chemistry with a proven track record.

    Find out more >

  • CADD

    CADD

    Accelerate hit-finding with high-throughput docking combined with pharmacophore and similarity searching.

    Find out more >

  • Biology

    Biology

    Comprehensive biology capabilities with expertise ranging from molecular biology to biomarker identification.

    Find out more >

  • ADMET/PK

    ADMET/PK

    A cascade of approaches ranging from early in vitro assessment to in vivo pharmacokinetics.

    Find out more >

  • Pharmaceutics

    Pharmaceutics

    Understanding and de-risking molecules as future pharmaceuticals.

    Find out more >

  • Respiratory Models

    Respiratory Models

    Expert mechanistic and predictive insight into human respiratory diseases.

    Find out more >

  • Early Safety Assessment

    Early Safety Assessment

    Integrated de-risking of drug candidates to identify your most robust molecules.

    Find out more >

Welcome to Argenta

We take as professional an approach to business relationships as we do to our science, with core principles that underpin how we work with our partners.

Argenta is a trusted strategic partner with significant industry experience in providing contract small molecule drug discovery services. Argenta offers a truly integrated approach to undertaking complete drug discovery programmes as well as hit identification, hit-to-lead, and lead optimisation projects. Our industry-seasoned, multi-disciplinary research teams work closely with our clients' scientists to enhance knowledge, add manpower, shorten time to development candidate identification, and increase the value of their drug discovery programmes.

Follow us on LinkedIn!

Our capability pathway

Our capability pathway

Find out more

Grant Application Support

Latest News

  • Charles River Laboratories Completes the Acquisition of the CRO Services Division of Galapagos NV

    Mon 31 Mar 2014

    WILMINGTON, Mass. -- (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus. The acquisition positions Charles River as a full service, early-stage contract research organization (CRO), with integrated in vitro and in vivo capabilities from target discovery through preclinical development....

    Read full article »


Next Events

  • Global Discovery & Development Innovation Forum

    London, UK

    13-14 May 2014
    Argenta will be represented by Heidi Kingdon Jones....

  • American Thoracic Society International Conference

    San Diego, USA

    16-21 May 2014...